Five hundred years ago, Christopher Columbus set forth to explore unknown lands. You might be asking, what do Chris and metastatic hormone receptor-positive breast cancer have in common? The answer lies in his diaries, a tale of two men, with one aptly providing anatomical details of our subject today. While we spend little time exploring Christopher, Michael and Josh meet and greet three famed Cyclin Dependant Kinase Inhibitors (CDK4/6) commonly known as Ribociclib, Abemaciclib and Palbociclib. While not all equal in stature, they have revolutionised metastatic breast cancer and now stand as first-line therapy and the gold standard of treatment. Tune in to find out why!

Visit us at your new website, www.inquisitiveonc.com, for our latest episodes, links to resources and musings!

Find us on Twitter @InquisitiveOnc

If you want us to look at a specific trial or subject, email us at [email protected]

Art courtesy of Taryn Silver. Music courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/

Note: This podcast is for educational purposes only. If you are unwell, seek medical advice, and for health, practitioners ensure you refer to your local institution's guidelines for treatment recommendations.

Hosted on Acast. See acast.com/privacy for more information.